NSE · ACCPL · Pharmaceuticals
Accretion Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹57 Cr with net profit ₹7 Cr — a 11.82% net margin, versus 11.13% the period before.
Shareholding
As of 2026-06-30
- Promoter73.52%
- Public23.72%
- DII2.76%
776 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.19× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #1 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,77,444 Cr | 176.1 | 5.71 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,19,101 Cr | 214.6 | 3.46 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,990 Cr | 88.75 | 4.13 | 18.59% | 18.86% |
| Lupin Limited | ₹1,11,885 Cr | 19.67 | 4.98 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹1,07,077 Cr | 192.91 | 6.57 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,246 Cr | 88.01 | 18.16 | 16.77% | 15.04% |
| Dr Reddys Laboratories Ltd. | ₹95,344 Cr | 431.06 | 2.52 | 0.11% | 0.12% |
| Aurobindo Pharma Ltd. | ₹92,388 Cr | 100.3 | 2.44 | 9.25% | 10.5% |
| Biocon Ltd. | ₹69,837 Cr | 545.38 | 2.05 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹67,823 Cr | 286.92 | 4.91 | 16.66% | 15.65% |
| Accretion Pharmaceuticals Ltd.(this company) | — | 18.97 | 3.35 | 17.67% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashAccretion Pharmaceuticals Ltd. operates in the Pharmaceuticals sector. The company reported a book value of Rs 49.21 and an EPS of 8.7. Its debt-to-equity ratio stands at 1.33. The 52-week high for the share price was Rs 171.15, and the 52-week low was Rs 53.8.
Positives
- +Annual revenue increased from Rs 13.41 Cr in Mar 2024 to Rs 57.47 Cr in Mar 2025.
- +Promoter holding is high at 73.5193% as of Mar 2026.
- +Return on capital employed (ROCE) is healthy at 46.32%.
- +Return on equity (ROE) is 17.67%.
Negatives
- −The company's profit margin is 0%, indicating no reported profit on sales.
- −The debt-to-equity ratio is 1.33, suggesting a relatively high level of debt.
- −No quarterly results have been disclosed for recent periods.
- −The total number of shareholders decreased from 1628 in Jun 2025 to 1182 in Mar 2026.
Financial Performance
In the fiscal year ending March 2025, Accretion Pharmaceuticals Ltd. recorded a revenue of Rs 57.47 Cr, a significant increase from Rs 13.41 Cr in March 2024. Net profit also rose to Rs 6.79 Cr in March 2025, compared to Rs 1.49 Cr in March 2024. EPS for March 2025 was 8.48, up from 1.96 in March 2024.
Profitability & Returns
The company’s return on equity (ROE) is 17.67%, while return on capital employed (ROCE) is 46.32%. The profit margin for the latest period is 0%. The EPS reported is 8.7.
Balance Sheet
Accretion Pharmaceuticals Ltd. has a book value per share of Rs 49.21. The debt-to-equity ratio is 1.33, indicating a moderate reliance on debt financing. The company does not currently offer a dividend yield, which is 0%.
Ownership & Pledges
Public shareholding stands at 26.4807%. There is no promoter pledging reported (0%). There are no DII or FII holdings for this period.
Regulatory & Surveillance
Accretion Pharmaceuticals Ltd. is currently under the ESM Framework, specifically ESM 1. This indicates additional surveillance measures are in place for the stock.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Accretion Pharmaceuticals Ltd.share price & fundamentals